228 related articles for article (PubMed ID: 31030017)
21. The role of disability and depression in cognitive functioning within 2 years after multiple sclerosis diagnosis.
Siepman TA; Janssens AC; de Koning I; Polman CH; Boringa JB; Hintzen RQ
J Neurol; 2008 Jun; 255(6):910-6. PubMed ID: 18484237
[TBL] [Abstract][Full Text] [Related]
22. Demographic features, behavioral measures, and clinical factors as predictors of cognitive function in patients with multiple sclerosis.
Alirezaei M; Forouzannia SM; Yarahmadi P; Sahraian MA; Owji M; Bidadian M; Ghadiri F; Naser Moghadasi A
Mult Scler Relat Disord; 2021 Apr; 49():102758. PubMed ID: 33567391
[TBL] [Abstract][Full Text] [Related]
23. Perceived fatigue and cognitive performance change in multiple sclerosis: Uncovering predictors beyond baseline fatigue.
Hu M; Muhlert N; Robertson N; Winter M
Mult Scler Relat Disord; 2019 Jul; 32():46-53. PubMed ID: 31030019
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing-Remitting Multiple Sclerosis: An Analysis of the DECIDE Dataset.
Castrogiovanni N; Mostert J; Repovic P; Bowen JD; Uitdehaag BMJ; Strijbis EMM; Cutter GR; Koch MW
Neurology; 2023 Jul; 101(1):e1-e11. PubMed ID: 37072219
[TBL] [Abstract][Full Text] [Related]
25. Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis.
Trenova AG; Slavov GS; Draganova-Filipova MN; Mateva NG; Manova MG; Miteva LD; Stanilova SA
Neurol Res; 2018 Mar; 40(3):153-159. PubMed ID: 29297273
[TBL] [Abstract][Full Text] [Related]
26. Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis.
Sonder JM; Burggraaff J; Knol DL; Polman CH; Uitdehaag BM
Mult Scler; 2014 Apr; 20(4):481-8. PubMed ID: 24019305
[TBL] [Abstract][Full Text] [Related]
27. Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis.
Riccitelli GC; Pagani E; Rodegher M; Colombo B; Preziosa P; Falini A; Comi G; Filippi M; Rocca MA
Mult Scler; 2019 Feb; 25(2):204-216. PubMed ID: 29173009
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of a brief electronic screening test for cognitive impairment in multiple sclerosis (SCI-MS Test).
Meca-Lallana JE; Prieto-González JM; Jimenez-Veiga J; Carreón-Guarnizo E; Jiménez-Martín I; Hernández-Clares R; Sistiaga-Berrondo A; Carles-Dies R; García-Molina E; Cerdán-Sánchez M; Costa-Arpín E; Croitoru I; Castillo-Triviño T; Iniesta-Martinez F; García-Pérez E; Olascoaga-Urtaza J
Mult Scler Relat Disord; 2019 Feb; 28():50-56. PubMed ID: 30553169
[TBL] [Abstract][Full Text] [Related]
29. Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study.
Brochet B; Deloire MS; Bonnet M; Salort-Campana E; Ouallet JC; Petry KG; Dousset V
Mult Scler; 2008 Nov; 14(9):1242-9. PubMed ID: 18653737
[TBL] [Abstract][Full Text] [Related]
30. The association between body mass index, demographic and clinical characteristics with cognitive performance in patients with neuromyelitis optica spectrum disorder.
Rezaeimanesh N; Saeedi R; Sahraian MA; Ghadiri F; Naser Moghadasi A
Curr J Neurol; 2022 Apr; 21(2):74-82. PubMed ID: 38011484
[No Abstract] [Full Text] [Related]
31. The Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS): results from the German validation study.
Filser M; Schreiber H; Pöttgen J; Ullrich S; Lang M; Penner IK
J Neurol; 2018 Nov; 265(11):2587-2593. PubMed ID: 30171410
[TBL] [Abstract][Full Text] [Related]
32. The Cambridge Neuropsychological Test Automated Battery (CANTAB) Versus the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) for the Assessment of Cognitive Function in Patients with Multiple Sclerosis.
Talebi M; Majdi A; Kamari F; Sadigh-Eteghad S
Mult Scler Relat Disord; 2020 Aug; 43():102172. PubMed ID: 32442887
[TBL] [Abstract][Full Text] [Related]
33. Validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in Greek population with multiple sclerosis.
Polychroniadou E; Bakirtzis C; Langdon D; Lagoudaki R; Kesidou E; Theotokis P; Tsalikakis D; Poulatsidou K; Kyriazis O; Boziki M; Papadopoulos G; Boura E; Sintila L; Hatzigeorgiou S; Ziamos C; Ioannidis P; Karacostas D; Grigoriadis N
Mult Scler Relat Disord; 2016 Sep; 9():68-72. PubMed ID: 27645348
[TBL] [Abstract][Full Text] [Related]
34. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.
Drake AS; Weinstock-Guttman B; Morrow SA; Hojnacki D; Munschauer FE; Benedict RH
Mult Scler; 2010 Feb; 16(2):228-37. PubMed ID: 20028710
[TBL] [Abstract][Full Text] [Related]
35. ApoE4-positive multiple sclerosis patients are more likely to have cognitive impairment: a cross-sectional study.
Mashayekhi F; Sadigh-Eteghad S; Naseri A; Asadi M; Abbasi Garravnd N; Talebi M
Neurol Sci; 2022 Feb; 43(2):1189-1196. PubMed ID: 34120271
[TBL] [Abstract][Full Text] [Related]
36. Motor assessment of upper extremity function and its relation with fatigue, cognitive function and quality of life in multiple sclerosis patients.
Yozbatiran N; Baskurt F; Baskurt Z; Ozakbas S; Idiman E
J Neurol Sci; 2006 Jul; 246(1-2):117-22. PubMed ID: 16678208
[TBL] [Abstract][Full Text] [Related]
37. Validation of the brief international cognitive assessment for multiple sclerosis (BICAMS) in the Portuguese population with multiple sclerosis.
Sousa C; Rigueiro-Neves M; Miranda T; Alegria P; Vale J; Passos AM; Langdon D; Sá MJ
BMC Neurol; 2018 Oct; 18(1):172. PubMed ID: 30332999
[TBL] [Abstract][Full Text] [Related]
38. A factor analytic investigation of the Mercy Evaluation of Multiple Sclerosis.
Merz ZC; Wright JD; Vander Wal JS; Gfeller JD
Clin Neuropsychol; 2018 Nov; 32(8):1431-1453. PubMed ID: 29359612
[TBL] [Abstract][Full Text] [Related]
39. Symbol digit modalities test predicts decline of off-road driving ability in Japanese patients with multiple sclerosis.
Maeta M; Mizuno M; Okubo S; Ogasawara M; Terauchi T; Suzuki M; Akasaka H; Sato Y; Ohi K; Maeda T
Mult Scler Relat Disord; 2022 Dec; 68():104150. PubMed ID: 36055114
[TBL] [Abstract][Full Text] [Related]
40. Cognitive impairment and decline in different MS subtypes.
Huijbregts SC; Kalkers NF; de Sonneville LM; de Groot V; Polman CH
J Neurol Sci; 2006 Jun; 245(1-2):187-94. PubMed ID: 16643951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
